SERA PROGNOSTICS, INC.

Sera Prognostics develops and commercializes blood-based biomarker tests focused on pregnancy-related conditions. The company's primary product is PreTRM, a non-invasive prenatal blood test that predicts a pregnant woman's risk of spontaneous preterm delivery. The company is expanding its test pipeline to address additional maternal health complications, including preeclampsia and fetal growth restriction, as well as developing broader pregnancy risk prediction capabilities.

The company operates as a medical laboratory services provider, processing blood samples and delivering predictive analytics to support clinical decision-making during pregnancy. Revenue is generated through test ordering and processing, primarily within the United States healthcare system. The business model relies on adoption among obstetricians and maternal-fetal medicine specialists.

Sera Prognostics operates with 63 full-time employees and maintains headquarters in Salt Lake City, Utah. The company is incorporated in Delaware and trades on Nasdaq, with a market capitalization of approximately $100 million. As a clinical-stage diagnostic company, the organization is scaling commercialization of its existing test while advancing its pipeline of pregnancy-related biomarker diagnostics.